BiotechTube
Home/RosVivo Therapeutics/Seungil Ro
SR

Seungil Ro

President and Chief Scientific Officer

RosVivo Therapeutics

Therapeutic Areas

Metabolic DiseasesDiabetesObesityNAFLDGastrointestinal Disorders

RosVivo Therapeutics Pipeline

DrugIndicationPhase
RSVI-301Diabetes (with planned expansion to Obesity, NAFLD, GI disorders)Pre-clinical
RSVI-302Diabetes and ObesityPre-clinical

Leadership Team at RosVivo Therapeutics

DC
David Craig
Chief Executive Officer
SM
Sandra M. Poudrier
Chief Operating Officer
View full RosVivo Therapeutics profile